- Home
- KPTI vs QNCX Comparison
KPTI vs QNCX Comparison
Compare KPTI & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- QNCX
- Stock Information
- Founded
- KPTI 2008
- QNCX 2012
- Country
- KPTI United States
- QNCX United States
- Employees
- KPTI N/A
- QNCX N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KPTI Health Care
- QNCX Health Care
- Exchange
- KPTI Nasdaq
- QNCX Nasdaq
- Market Cap
- KPTI 44.5M
- QNCX 47.7M
- IPO Year
- KPTI 2013
- QNCX 2019
- Fundamental
- Price
- KPTI $4.74
- QNCX $1.78
- Analyst Decision
- KPTI Strong Buy
- QNCX Strong Buy
- Analyst Count
- KPTI 7
- QNCX 5
- Target Price
- KPTI $45.43
- QNCX $8.00
- AVG Volume (30 Days)
- KPTI 146.2K
- QNCX 320.7K
- Earning Date
- KPTI 08-05-2025
- QNCX 08-12-2025
- Dividend Yield
- KPTI N/A
- QNCX N/A
- EPS Growth
- KPTI N/A
- QNCX N/A
- EPS
- KPTI N/A
- QNCX N/A
- Revenue
- KPTI $142,126,000.00
- QNCX N/A
- Revenue This Year
- KPTI $2.09
- QNCX N/A
- Revenue Next Year
- KPTI $12.90
- QNCX N/A
- P/E Ratio
- KPTI N/A
- QNCX N/A
- Revenue Growth
- KPTI 1.19
- QNCX N/A
- 52 Week Low
- KPTI $3.51
- QNCX $0.51
- 52 Week High
- KPTI $16.95
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- KPTI 41.48
- QNCX 68.77
- Support Level
- KPTI $4.23
- QNCX $1.55
- Resistance Level
- KPTI $5.14
- QNCX $2.05
- Average True Range (ATR)
- KPTI 0.38
- QNCX 0.17
- MACD
- KPTI 0.04
- QNCX 0.02
- Stochastic Oscillator
- KPTI 24.45
- QNCX 64.00
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.